Bladder Cancer Trial, Recruiting NCT07225205 Sponsor: Johns Hopkins University Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT07225205
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with a type of bladder cancer called urothelial carcinoma, confirmed by a pathology test, including types that have or have not grown into the bladder muscle, as well as certain variant forms
  • People who have decided, after discussion with a specialist cancer surgeon, to have their bladder surgically removed along with nearby lymph nodes in the pelvis

Who may not be able to join:

  • People having bladder removal surgery for non-cancer reasons, such as chronic bladder pain, abnormal connections between organs (fistulas), or severe urinary problems
  • People having bladder removal surgery because a cancer from another organ (such as the rectum, colon, or uterus) has spread or extended into the bladder
  • People whose cancer has spread so extensively in the pelvis that a larger operation to remove multiple pelvic organs would be required
  • People who have pre-existing heart, kidney, or liver problems that would prevent them from safely receiving a particular type of fluid therapy at home (confirm with trial site)
  • People who are unwilling or unable to take part in follow-up phone calls at 30 and 90 days after their procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Max Kates, MD, Johns Hopkins School of Medicine

Phone: 410-955-6100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of participants with 90-day Hospital Readmission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov